Therapeutic candidate being advanced for the potential treatment of conditions involving inflammation and fibrosis, including idiopathic pulmonary fibrosis (IPF). Also being advanced under the Animal Rule for medical countermeasures; plans underway to study LYT-100 in progressive fibrosing interstitial lung disease (PF-ILDs) as well as other fibrotic conditions where there is human data with pirfenidone suggestive of clinical benefit.

Fully human IgG4 monoclonal antibody, or mAb, designed to inhibit the activity of galectin-9, an immunomodulatory molecule expressed by tumors and immune cells and shown to suppress the immune system from recognizing and destroying cancer cells. We are developing LYT-200 for the treatment of metastatic/locally advanced solid tumors that have poor survival rates, including urothelial and head and neck cancers. We are also developing LYT-200 for the treatment of hematological malignancies, such as acute myeloid leukemia (AML).

Designed to overcome the poor oral bioavailability of allopregnanolone to advance what we believe could be a best-in-class new medicine for treating anxiety, mood disorders and Fragile X-associated Tremor/ Ataxia Syndrome. Allopregnanolone is a positive allosteric modulator of GABA_A receptors that has therapeutic potential across a wide range of neurological conditions, including anxiety and Fragile X-associated Tremor/ Ataxia Syndrome, though its therapeutic application has been limited due to high first pass metabolism. Our Glyph platform reversibly links a drug to a lipid, creating a novel prodrug. We believe this technology has the potential to provide a broadly applicable means of enhancing the bioavailability of certain orally administered drugs that would otherwise be limited by first-pass liver metabolism.

Therapeutic candidate designed to unlock the validated efficacy of cannabidiol (CBD). Derived from the Glyph platform, LYT-310 offers oral dosing and the potential for improved tolerability, which could expand the therapeutic application of CBD across a wider range of age groups and indications, including both rare and more common forms of epilepsy and other neurological indications.